适度低分离的前列腺癌早期激进放射治疗:一种倾向性得分匹配分析,比较剂量分离模式
Yinjie Tao1, Weishi Cheng1,2, Hongnan Zhen1
1Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Cancer control : journal of the Moffitt Cancer Center
|April 12, 2025
概括
这项研究比较了两种适度低分离放射治疗 (MHRT) 方案,用于早期前列腺癌. 两种MHRT模式都显示出相似的生存结果和毒性概况,支持MHRT.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 中度低分离放射治疗 (MHRT) 是一种正在发展中的治疗早期前列腺癌的方法.
- 对比不同的MHRT分离计划对于优化治疗疗效和患者结果至关重要.
- 了解生存效益和治疗毒性之间的平衡对于临床决策至关重要.
研究的目的:
- 评估和比较两种MHRT疗法在前列腺癌早期阶段的临床结果,生存益处和毒性.
- 具体来说,要比较60Gy在20个分数 (60Gy/20f) 和70Gy在28个分数 (70Gy/28f) 中.
- 评估这些MHRT模式对整体存活率 (OS),无病存活率 (DFS) 和与治疗相关的毒性影响.
主要方法:
- 对187名2014年至2023年期间接受治疗的前列腺癌早期患者的回顾性分析.
- 使用倾向性得分匹配来确保可比性组进行疗效评估.
- 卡普兰-梅尔分析用于计算OS和DFS;毒性使用不良事件标准v5.0.0.进行评估.
主要成果:
- 在匹配后,每个组中有73名患者 (60 Gy / 20f和70 Gy / 28f),随访时间中位数为36.0个月.
- 两组之间在3年后的OS (92.4% vs 89.0%,P=0.375) 或DFS (91.0% vs 81.0%,P=0.096) 中没有观察到统计学意义上的差异.
- 急性尿道毒性 (等级≥2) 是相同的 (9.6%对9.6%,P=1.0),但70 Gy组晚期尿道毒性较少 (2.8%对12.3%,P=0.028);GI毒性是可比的.
结论:
- 两种MHRT分离模式 (60 Gy/20f和70 Gy/28f) 在前列腺癌早期阶段显示出可比的生存结果和毒性概况.
- MHRT是早期前列腺癌的可行的初级治疗选择.
- 60 Gy/20f疗法在生存结果方面显示出边际的,虽然不是统计学上显著的优势.
相关概念视频
Hazard Ratio
71
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
71
Cancer Survival Analysis
308
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
308


